{"id":"lorlatinib-plus-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Myelosuppression (from chemotherapy component)"},{"rate":null,"effect":"Neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lorlatinib selectively inhibits anaplastic lymphoma kinase (ALK) and ROS1, blocking aberrant signaling in ALK-fusion positive tumors. The addition of chemotherapy provides complementary cytotoxic activity to enhance overall anti-tumor efficacy and potentially overcome resistance mechanisms.","oneSentence":"Lorlatinib is an ALK tyrosine kinase inhibitor combined with chemotherapy to target ALK-positive cancers while enhancing cytotoxic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:09.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"ALK-positive non-small cell lung cancer (NSCLC)"},{"name":"ALK-positive advanced or metastatic lung cancer"}]},"trialDetails":[{"nctId":"NCT06333899","phase":"EARLY_PHASE1","title":"Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2025-08-03","conditions":"High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma","enrollment":15},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT05297890","phase":"PHASE2","title":"A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2022-05-27","conditions":"Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer","enrollment":70},{"nctId":"NCT05384626","phase":"PHASE1, PHASE2","title":"A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)","status":"RECRUITING","sponsor":"Nuvalent Inc.","startDate":"2022-06-09","conditions":"Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":840},{"nctId":"NCT03107988","phase":"PHASE1","title":"NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2017-09-05","conditions":"Neuroblastoma","enrollment":65},{"nctId":"NCT06893354","phase":"PHASE4","title":"Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2025-05-10","conditions":"NSCLC","enrollment":20},{"nctId":"NCT06858410","phase":"PHASE3","title":"Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2025-03","conditions":"Neoadjuvant Non-Small Cell Lung Cancer","enrollment":36},{"nctId":"NCT04322890","phase":"PHASE2","title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-04-16","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation","enrollment":6000},{"nctId":"NCT06532149","phase":"","title":"ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-08-05","conditions":"NSCLC Stage IV, Sex Disorder, Hypogonadism, Male","enrollment":80},{"nctId":"NCT03546894","phase":"","title":"A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-07-23","conditions":"Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung","enrollment":111},{"nctId":"NCT06378892","phase":"PHASE2","title":"A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib","status":"RECRUITING","sponsor":"Centro di Riferimento Oncologico - Aviano","startDate":"2024-03-15","conditions":"Non Small Cell Lung Cancer Metastatic, ALK Gene Mutation","enrollment":45},{"nctId":"NCT05948462","phase":"PHASE2","title":"Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib","status":"WITHDRAWN","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-11","conditions":"Lung Cancer, Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT04541407","phase":"PHASE1","title":"Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-10-29","conditions":"Non Small Cell Lung Cancer, CNS Progression","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"lorlatinib plus chemotherapy","genericName":"lorlatinib plus chemotherapy","companyName":"The First Affiliated Hospital of Guangzhou Medical University","companyId":"the-first-affiliated-hospital-of-guangzhou-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lorlatinib is an ALK tyrosine kinase inhibitor combined with chemotherapy to target ALK-positive cancers while enhancing cytotoxic effects. Used for ALK-positive non-small cell lung cancer (NSCLC), ALK-positive advanced or metastatic lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}